Navigation Links
Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients
Date:4/23/2009

egimen achieved SVR. RVR is defined as undetectable virus (HCV RNA) in plasma at 4 weeks after the addition of boceprevir. In the lead-in arms, 64 percent of patients achieved RVR. Fewer patients in the lead-in arms discontinued treatment due to viral breakthrough.

"These results are very exciting and provide important insights to help further define response guided therapy using a P/R lead-in boceprevir regimen with peginterferon and ribavirin backbone treatment," said Paul Kwo, M.D., associate professor of medicine and medical director, liver transplantation, Department of Medicine, Division of Gastroenterology/Hepatology, Indiana University School of Medicine, Indianapolis, and lead investigator of the study. "Building on these results, the boceprevir Phase III clinical program individualizes treatment based on response, utilizing RVR criteria at week 4 of boceprevir treatment to determine overall duration of therapy. Based on the RVR rate seen in this Phase II study, we are hopeful that the majority of patients can be treated with 28 weeks of therapy."

Part II of the HCV SPRINT-1 study explored a low-dose ribavirin strategy in which boceprevir was given in combination with PEGINTRON and low-dose REBETOL for 48 weeks. SVR for the low-dose REBETOL arm was 36 percent (n=21/59) compared to 50 percent for a 48-week control arm with PEGINTRON and standard-dose REBETOL plus boceprevir (n=8/16). In contrast to the results seen in Part I, the low-dose REBETOL regimen was associated with increased viral breakthrough during treatment, higher relapse rates after the end of treatment and lower SVR, strongly indicating that standard-dose ribavirin is required to optimize response.

Another key finding of the HCV SPRINT-1 study is that treatment-emergent anemia appeared to be associated with higher SVR, with anemic patients (hemoglobin decreasing to less than 10 g/dL) having higher SVR rates than those wi
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
2. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
3. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
4. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
5. Final Data From the SEISMIC Trial Suggest Safety, Efficacy of Autologous Stem- Cell Therapy for Treating Congestive Heart Failure
6. Final Data From the Bioheart Seismic Trial Suggest Safety, Efficacy of Autologous Stem-Cell Therapy for Treating Congestive Heart Failure
7. Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit
8. Nventa Completes Safety Evaluation on Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
9. Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL)
10. The Anatomy of Clinical Trials: Greys Season Finale Leaves Public in the Dark About the Myths and Realities
11. Final Results of the CellCept(R) Spare the Nephron (STN) Study Show Maintenance Therapy is Associated with Improved Renal Function
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... 3, 2015 Report Details What ... areas are going to grow at the fastest rates? ... 2025, assessing data, trends, opportunities and prospects there. ... graphs. Discover the most lucrative areas in the industry ... you assess forecasted sales at overall world market and ...
(Date:9/3/2015)... YORK , Sept. 3, 2015 ... Your New Guide to that Market, its R&D and Sales ... to assess the future of cancer-treating medicines? Visiongain,s new report ... you stay ahead. There you discover financial data, R&D trends, ... In our analysis you see forecasted sales to ...
(Date:9/3/2015)... LONDON, Sept. 3, 2015 With a population ... largest country and therefore also its single largest potential ... years, China has led all major world economies in ... health expenditures, and government health expenditures. As an in ... developed markets of the United States, western European countries, ...
Breaking Medicine Technology:Ophthalmic Devices Market Forecast 2015-2025: Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 2Ophthalmic Devices Market Forecast 2015-2025: Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 3Ophthalmic Devices Market Forecast 2015-2025: Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 4World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 2World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 3World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 4World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 5World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 6World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 7IVD in China 2IVD in China 3IVD in China 4IVD in China 5IVD in China 6IVD in China 7IVD in China 8IVD in China 9IVD in China 10IVD in China 11IVD in China 12IVD in China 13
(Date:9/3/2015)... (PRWEB) , ... September 03, 2015 , ... ... the academic partner for the Academy of Integrative Health & Medicine (AIHM) Interprofessional ... the direction of Tieraona Low Dog, MD, an internationally renowned educator, physician and ...
(Date:9/3/2015)... ... September 03, 2015 , ... ... in Patient Experience Conference 2016, to be held April 13-15 at Sheraton Hotel ... hosted event bringing together the collective voices of healthcare leaders, staff, physicians, patients ...
(Date:9/3/2015)... Rhinebeck, NY (PRWEB) , ... September 03, 2015 ... ... Kitslaar when he made the company the final destination of his six-month, 10,000 ... , During the trek—which he calls the “Connecting Las Americas” ...
(Date:9/3/2015)... ... September 03, 2015 , ... BedJet released a new ... v2, for pre-order on Kickstarter. Today the BedJet v2 pre-order campaign blazed ... top 0.1% most successful campaigns ever on crowdfunding giant Kickstarter. , Simple to use ...
(Date:9/3/2015)... ... September 03, 2015 , ... Real Time Pain Relief ... professional bull rider David Mason has signed an official endorsement deal with the company. ... of six and his first bull at 15. He is an Australian bull riding ...
Breaking Medicine News(10 mins):Health News:Oregon Collaborative for Integrative Medicine Partners with AIHM on First Interprofessional Fellowship 2Health News:Oregon Collaborative for Integrative Medicine Partners with AIHM on First Interprofessional Fellowship 3Health News:Patient Experience Conference 2016 Program Announced by The Beryl Institute 2Health News:Patient Experience Conference 2016 Program Announced by The Beryl Institute 3Health News:Topical BioMedics Announces Visit from Max Wohlgemuth Kitslaar, Ending his Six-Month, 10,000 Mile Journey from Chile to New York on a 1976 Moto Guzzi Motorcycle 2Health News:Topical BioMedics Announces Visit from Max Wohlgemuth Kitslaar, Ending his Six-Month, 10,000 Mile Journey from Chile to New York on a 1976 Moto Guzzi Motorcycle 3Health News:Topical BioMedics Announces Visit from Max Wohlgemuth Kitslaar, Ending his Six-Month, 10,000 Mile Journey from Chile to New York on a 1976 Moto Guzzi Motorcycle 4Health News:Topical BioMedics Announces Visit from Max Wohlgemuth Kitslaar, Ending his Six-Month, 10,000 Mile Journey from Chile to New York on a 1976 Moto Guzzi Motorcycle 5Health News:Topical BioMedics Announces Visit from Max Wohlgemuth Kitslaar, Ending his Six-Month, 10,000 Mile Journey from Chile to New York on a 1976 Moto Guzzi Motorcycle 6Health News:BedJet Hits $1 million in Sales in 28 Days on Kickstarter after Shark Tank Rejection 2Health News:BedJet Hits $1 million in Sales in 28 Days on Kickstarter after Shark Tank Rejection 3Health News:Real Time Pain Relief Sponsors the Talented PBR Bull Rider from Down Under - David Mason 2Health News:Real Time Pain Relief Sponsors the Talented PBR Bull Rider from Down Under - David Mason 3
... ... Geriatrics Association shows a new virtual reality device, the GaitAid, can help stroke patients learn to ... Haifa, Israel (PRWEB) February ... stroke each year. It is one of the leading causes of adult disability in the U.S. ...
... ATLANTA--A new study has found that many male cancer ... radiation therapy have an impaired quality of life and ... , a peer-reviewed journal of the American Cancer Society, ... testosterone deficiency may benefit from testosterone replacement therapy. ...
... , ... ... ... ...
... ... opens it newest location in beautiful Olde Towne Gaithersburg Maryland. Funeral Directors assist ... and multicultural community. , ... Gaithersburg, MD (PRWEB) February 21, 2010 -- A new, affordable option in funeral ...
... three million children have been born as a result of ... tube baby" in 1978. While the majority of these ... at greater risk of certain kinds of birth defects and ... and type 2 diabetes later in life. Carmen Sapienza, ...
... ... Lauderdale, now offers both the Cisco CCNA Security (prerequisite) and Cisco CCSP Certification Courses ... ... as a prerequisite course. These courses may now be taken at the warm ...
Cached Medicine News:Health News:New Successful Treatment Improves Walking Post Stroke 2Health News:WellPoint/Blue Cross Liver Transplant Denial Trial Starts Monday 2Health News:WellPoint/Blue Cross Liver Transplant Denial Trial Starts Monday 3Health News:WellPoint/Blue Cross Liver Transplant Denial Trial Starts Monday 4Health News:WellPoint/Blue Cross Liver Transplant Denial Trial Starts Monday 5Health News:Olde Towne Gaithersburg Welcomes Thibadeau Mortuary - A Lower-Cost Alternative In Funeral and Cremation Service 2Health News:Olde Towne Gaithersburg Welcomes Thibadeau Mortuary - A Lower-Cost Alternative In Funeral and Cremation Service 3Health News:Cisco CCSP Now Requires CCNA Security as Prerequisite 2Health News:Cisco CCSP Now Requires CCNA Security as Prerequisite 3
Used for access and catheterization procedures. Double flexible tipped design permits alternative use of both ends of wire guide depending upon procedural needs. Supplied sterile in peel-open package...
... Coronary Stent System is Guidant's first in ... Cobalt chromium is stronger and more radiopaque ... stent can have similar strength and visibility ... struts that are only .0032" thick. Thinner ...
Stent delivery with extra rail support...
Forte Guide Wire w/Markers: Front line use, 1:1 torque, excellent steering and tracking, sharp vessel images, floppy and moderate support....
Medicine Products: